Last updated: September 7, 2026
GONAL-F RFF is Merck KGaA’s recombinant follitropin alfa product for controlled ovarian stimulation in assisted reproductive technology and, in selected patients, anovulatory infertility. Its commercial position remains strong because of brand recognition, physician familiarity, pen-based delivery, and global fertility demand. Its financial trajectory is mature rather than high-growth: sales depend on treatment volumes, geographic mix, reimbursement, fertility-clinic purchasing, and competition from other gonadotropins and lower-cost recombinant products.
Merck does not generally disclose standalone GONAL-F RFF revenue. Public reporting groups the product within the Healthcare segment’s Fertility franchise, so product-level revenue, margin, and market-share estimates require third-party data or company disclosures not included in annual reports. Merck’s public financial statements support a franchise-level analysis, not a precise GONAL-F RFF income statement.[1]
What is GONAL-F RFF and how does it generate revenue?
GONAL-F RFF contains follitropin alfa, a recombinant form of human follicle-stimulating hormone. It is supplied in multidose formulations and prefilled pen presentations, including GONAL-F RFF Pen and GONAL-F RFF Redi-ject. The product is used in fertility treatment protocols involving ovarian stimulation, ovulation induction, and assisted reproductive technology.[2]
The product generates revenue through:
- Retail and specialty-pharmacy prescriptions.
- Fertility-clinic and hospital procurement.
- Government and private reimbursement.
- International distributor and affiliate sales.
- Pen and cartridge presentations with recurring treatment demand.
GONAL-F RFF is not a one-time therapy. Patients undergoing in vitro fertilization may require repeated daily dosing across a stimulation cycle, although dose and treatment duration vary by ovarian reserve, age, protocol, and response. Revenue therefore correlates more closely with treatment-cycle volume and units per cycle than with the number of treated patients alone.
How large is the fertility-drug market?
The fertility-drug market is supported by rising use of IVF, delayed childbearing, improved access to fertility services, and expanded fertility-preservation activity. Demand is concentrated in North America, Western Europe, China, Japan, Australia, and selected Middle Eastern markets.
The principal market-growth drivers are:
| Driver |
Effect on GONAL-F RFF |
| More IVF and intracytoplasmic sperm injection cycles |
Increases gonadotropin demand |
| Delayed parenthood |
Expands the treated infertility population |
| Fertility preservation |
Creates incremental ovarian-stimulation demand |
| Increased clinic capacity |
Supports prescription volume |
| Public reimbursement |
Improves patient access and cycle initiation |
| Biosimilar or lower-cost recombinant FSH |
Creates price pressure |
| Single-embryo-transfer protocols |
May reduce medication use per successful birth |
| Better ovarian-response monitoring |
Can reduce excess dosing |
The commercial opportunity is structurally attractive, but the market is sensitive to household income, reimbursement restrictions, clinic financing, and regulatory policy. Fertility treatments are often only partially reimbursed or are self-funded. This makes price and discounting more important than in fully reimbursed chronic-care markets.
What is the financial trajectory for GONAL-F RFF?
GONAL-F RFF should be classified as a mature, cash-generative fertility brand rather than a launch-stage growth asset. Merck’s public reporting does not isolate product revenue. The company reports Fertility as a broader commercial category that includes other fertility products and geographic markets.[1]
Revenue trajectory
The likely revenue pattern has four phases:
| Period |
Commercial condition |
Financial effect |
| Launch and adoption |
Physician and clinic uptake of recombinant FSH |
Rapid volume growth |
| Brand expansion |
Broader international access and pen adoption |
Revenue and mix improvement |
| Maturity |
Stable treatment demand and established prescriber base |
Lower growth, recurring cash flow |
| Post-exclusivity competition |
Generic, biosimilar, or alternative-product pressure |
Price and share erosion |
GONAL-F RFF’s mature revenue base is supported by repeat treatment cycles and established clinical protocols. Growth is more likely to come from market expansion, treatment access, and improved penetration in emerging markets than from significant price increases in developed markets.
Merck’s fertility business has remained strategically important within Healthcare, but the company’s annual reporting does not provide a GONAL-F-specific revenue series. Any claim that the product generated a particular annual dollar amount would exceed the public disclosure level in Merck’s audited reports.
Margin profile
The product’s gross-margin profile is likely supported by:
- Recombinant manufacturing know-how.
- Established scale.
- Brand and physician familiarity.
- Pen-device differentiation.
- Recurring demand from treatment cycles.
Margin pressure comes from:
- Rebates to fertility clinics and specialty pharmacies.
- Payer restrictions.
- Tender pricing outside the United States.
- Lower-priced recombinant FSH products.
- Manufacturing and quality-control costs for a recombinant protein.
- Device, cartridge, and packaging complexity.
As a mature biologic, GONAL-F RFF can retain attractive margins after core patent expiry if manufacturing scale, regulatory know-how, and brand trust limit substitution. The main commercial risk is gradual price compression rather than an immediate loss of all sales.
How does GONAL-F RFF compare with competing fertility drugs?
GONAL-F RFF competes primarily with recombinant follitropin products and urinary-derived gonadotropins.
| Product |
Active ingredient or class |
Main competitive distinction |
| GONAL-F RFF |
Recombinant follitropin alfa |
Established brand, pen delivery, broad global presence |
| Follistim AQ |
Recombinant follitropin beta |
Direct recombinant-FSH competitor, particularly important in the U.S. |
| Bemfola |
Recombinant follitropin alfa |
Lower-cost or biosimilar-style competition in selected markets |
| Ovaleap |
Recombinant follitropin alfa |
European recombinant-FSH competitor |
| Puregon |
Recombinant follitropin beta |
International recombinant-FSH alternative |
| Menopur |
Human menopausal gonadotropin |
Provides FSH and LH activity; used in different clinical protocols |
| Rekovelle |
Follitropin delta |
Dose-selection and individualized stimulation positioning |
| Corifollitropin alfa products |
Long-acting FSH |
Reduced injection frequency in selected protocols |
GONAL-F RFF’s strongest direct competition comes from other recombinant FSH products. Menopur competes at the protocol level rather than as an identical molecule because it provides a different gonadotropin profile. Rekovelle competes through individualized dosing and reduced injection burden, which can affect the economics of a complete stimulation cycle.
What formulation and delivery patents protect GONAL-F RFF?
GONAL-F RFF’s commercial protection has historically relied on a combination of active-ingredient, recombinant-production, formulation, container, cartridge, and pen-device rights. The most important commercial protections are now mature or expired in major markets.
The relevant protection categories are:
- Recombinant follitropin alfa production and purification.
- Protein formulation and stability.
- Multidose cartridge technology.
- Prefilled pen delivery.
- Injection-device mechanics and dose selection.
- Manufacturing controls that support product consistency.
The product is a biologic, but that does not mean every manufacturing process or delivery device remains protected after core exclusivity ends. Device patents can expire independently from composition or process patents. Regulatory approval of a competing product also depends on comparability, clinical data, manufacturing validation, and jurisdiction-specific requirements.
What is the Orange Book status of GONAL-F RFF?
GONAL-F RFF was approved in the United States under a drug application rather than through a modern biosimilar pathway. The FDA labeling identifies the product and its approved fertility indications, dosage forms, and administration requirements.[2]
No currently material U.S. patent barrier is generally associated with the core follitropin alfa molecule. The principal U.S. commercial issue is therefore market access and product substitution, not a recently issued composition-of-matter patent. Orange Book listings and patent certifications can change, and a product’s absence of a current blocking patent does not eliminate manufacturing, device, or regulatory barriers.
When did GONAL-F RFF lose exclusivity?
Core market exclusivity for recombinant follitropin alfa ended years ago in major jurisdictions. GONAL-F RFF is no longer protected by a launch-era exclusivity position comparable to a newly approved biologic.
The practical timeline is:
| Protection stage |
Commercial status |
| Original recombinant FSH protection |
Expired or commercially exhausted in major markets |
| Product-specific formulation rights |
Mature; some rights may have expired by jurisdiction |
| Pen and cartridge rights |
Potentially separate from active-ingredient protection |
| Regulatory exclusivity |
Expired for the original U.S. approvals |
| Current protection |
Brand, manufacturing, quality, device, and regulatory execution |
The loss of exclusivity has not eliminated the brand. Fertility physicians often continue using established products because stimulation protocols, dose algorithms, clinic purchasing, and patient instruction are operationally embedded.
Are there Paragraph IV challenges or biosimilar risks?
Paragraph IV litigation is not the primary current risk profile for GONAL-F RFF. Paragraph IV challenges target patents listed in the FDA Orange Book and are most relevant when an abbreviated new drug application seeks approval before listed patents expire.
For GONAL-F RFF, the more relevant competitive routes are:
- Follow-on recombinant FSH products.
- Biosimilar or biologic follow-on applications in jurisdictions that permit them.
- Region-specific products approved under abbreviated biologic pathways.
- Substitution by different FSH molecules or long-acting products.
- Clinic-level switching based on price and supply.
The biosimilar risk is moderate to high over the long term, but substitution is unlikely to be instantaneous. Follitropin products require sensitive biologic manufacturing, comparability data, pharmacodynamic assessment, quality validation, and market-specific regulatory approval. Physician confidence and fertility-clinic protocol preferences also affect uptake.
In Europe, follow-on follitropin products have created more direct price competition than in the United States. The U.S. market has historically had fewer direct interchangeable options, although competition can still arise through separate biologic or drug applications and through competing branded products.
Which companies challenge GONAL-F RFF?
The principal competitive companies are:
- Organon, through Follistim and related fertility products.
- Ferring Pharmaceuticals, through Menopur and Rekovelle.
- Gedeon Richter, through Bemfola and other fertility products in selected markets.
- Theramex and regional fertility suppliers.
- Local manufacturers and distributors in China, Latin America, the Middle East, and other non-U.S. markets.
Competition occurs through molecule selection, dose convenience, clinic contracting, patient support, reimbursement positioning, and supply reliability. A competing product does not need to be clinically identical to take share. It can win by reducing injections, lowering acquisition cost, fitting a clinic’s protocol, or securing preferred payer status.
What is the FDA regulatory status of GONAL-F RFF?
GONAL-F RFF is FDA-approved for controlled ovarian stimulation in patients undergoing assisted reproductive technology and for selected anovulatory infertility indications. The labeling includes dosing, administration, contraindications, warnings, ovarian hyperstimulation syndrome risks, multiple-birth risks, and monitoring requirements.[2]
The product is administered by subcutaneous injection. The pen format is commercially important because it supports dose adjustment and patient self-administration. The regulatory value of the pen is therefore practical rather than purely patent-based.
GONAL-F RFF is not a biosimilar to another reference product. It is the original recombinant follitropin alfa product in its relevant approval history. Its competitive exposure comes from follow-on and alternative gonadotropin products.
What patent litigation affects GONAL-F RFF?
No major current patent litigation is central to the public commercial profile of GONAL-F RFF. The key litigation risk is historical or product-specific rather than a live, high-value dispute involving a recently expiring core patent.
Potential disputes could still involve:
- Pen-device patents.
- Cartridge and container systems.
- Manufacturing processes.
- Product labeling and method-of-use claims.
- Biosimilar or follow-on approval timing.
- Trade secrets and process know-how.
The absence of a current headline patent case does not mean the product has no defensible assets. Manufacturing consistency, regulatory files, supplier qualification, and quality systems can delay competition even where patent protection is limited.
What geographic markets matter most?
The United States remains important because of product value, specialist fertility clinics, and branded prescription economics. Europe is strategically important but generally more exposed to tendering, health-system reimbursement controls, and follow-on competition. China and other Asian markets offer volume growth but carry greater pricing, registration, local-competition, and procurement risks.
| Region |
Market opportunity |
Main risk |
| United States |
Brand value and specialty fertility demand |
Payer controls and competing recombinant FSH |
| Western Europe |
Large assisted-reproduction base |
Tender pricing and follow-on products |
| China |
Expanding fertility treatment access |
Local competition and procurement pressure |
| Japan |
Established fertility infrastructure |
Regulatory and reimbursement constraints |
| Emerging markets |
Untapped treatment demand |
Affordability and distribution barriers |
What generic launch scenarios exist for GONAL-F RFF?
Three scenarios are commercially relevant.
Base case
GONAL-F RFF retains a meaningful branded share. Revenue is broadly stable to moderately declining, with volume growth offsetting price pressure. The pen and clinic familiarity support continued use.
Downside case
A lower-cost follow-on product secures reimbursement or clinic contracts. GONAL-F RFF loses share and faces net-price erosion, especially in Europe and price-sensitive markets.
Upside case
IVF and fertility-preservation volumes expand faster than price declines. Merck preserves share through supply reliability, physician confidence, patient support, and continued pen adoption.
The most probable long-term outcome is gradual erosion rather than a sharp cliff. Fertility-drug markets are protocol-driven, and clinicians may not switch products solely on list price.
How strong is the GONAL-F RFF patent estate?
The patent estate is weak as a remaining exclusivity barrier but stronger as a commercial execution platform.
| Asset category |
Current strategic strength |
| Core active ingredient |
Low remaining exclusivity value |
| Original biologic approval |
Mature |
| Formulation |
Limited remaining blocking value by jurisdiction |
| Pen and cartridge |
Potentially useful, but claim scope and expiry matter |
| Manufacturing know-how |
High practical value |
| Brand and physician familiarity |
High commercial value |
| Regulatory package and quality systems |
High barrier for new entrants |
| Distribution and clinic relationships |
High but contestable |
GONAL-F RFF’s defensibility depends less on a single patent than on cumulative execution. This supports continued cash generation but does not prevent gradual competition.
Key Takeaways
- GONAL-F RFF is a mature recombinant follitropin alfa franchise owned by Merck KGaA.
- Merck does not publicly report standalone GONAL-F RFF revenue.
- The product’s financial trajectory depends on IVF volume, fertility access, reimbursement, clinic purchasing, and international mix.
- Core patent and regulatory exclusivity are mature in major markets.
- Direct competition comes from Follistim, Bemfola, Ovaleap, Puregon, Menopur, and Rekovelle.
- Biosimilar and follow-on risk is higher in Europe than in the United States.
- The main commercial risk is gradual price and share erosion, not an immediate patent cliff.
- Manufacturing know-how, pen delivery, brand familiarity, and clinic relationships remain important non-patent defenses.
- GONAL-F RFF is more likely to remain a cash-generating mature brand than a high-growth biologic.
FAQs
Is GONAL-F RFF a biologic drug?
Yes. GONAL-F RFF contains recombinant follitropin alfa, a recombinant glycoprotein hormone produced through biologic manufacturing.
Is GONAL-F RFF interchangeable with Follistim?
No automatic clinical or regulatory interchangeability should be assumed. Follistim contains follitropin beta, while GONAL-F RFF contains follitropin alfa. Product selection depends on approval status, physician judgment, protocol, payer rules, and availability.
Does GONAL-F RFF have biosimilar competition?
Follow-on recombinant FSH competition exists in several markets, particularly Europe. The intensity of competition varies by jurisdiction, approval pathway, reimbursement policy, and clinic contracting.
What is the main financial risk for GONAL-F RFF?
The main risk is gradual net-price and market-share erosion caused by lower-cost recombinant FSH products, clinic tenders, reimbursement restrictions, and alternative stimulation protocols.
Can GONAL-F RFF revenue grow after patent expiry?
Yes. Revenue can grow through increased IVF volumes, fertility preservation, geographic expansion, improved access, and continued brand retention. Patent expiry limits pricing power but does not eliminate demand or brand value.
References
-
Merck KGaA. (2024). Annual report 2023. Darmstadt, Germany: Merck KGaA.
-
U.S. Food and Drug Administration. (2023). GONAL-F RFF prescribing information. Silver Spring, MD: U.S. Department of Health and Human Services.
-
European Medicines Agency. (2024). GONAL-f: EPAR product information. Amsterdam, Netherlands: European Medicines Agency.
-
European Society of Human Reproduction and Embryology. (2023). ART fact sheet and fertility-treatment data. Brussels, Belgium: ESHRE.
-
U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products. Silver Spring, MD: U.S. Department of Health and Human Services.
